Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update

SAN DIEGO, May 13, 2022 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2022…

Click here to view original post